NeuroPace Inc. (NPCE) intrinsic value & 10-year financials
NeuroPace Inc. (NPCE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 19.4% a year to $100.0M, with an average return on invested capital of 48.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $12.24
- Market cap
- $400.5M
- Revenue (FY2025)
- $100.0M
- Revenue growth (7-yr CAGR)
- 19.4%
- ROIC (10-yr avg)
- 48.4%
- Free cash flow (FY2025)
- -$11.3M
NPCE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $100.0M | -$21.5M | -$0.66 | -$11.3M | -16.3% | -24.7% |
| FY2024 | $79.9M | -$27.1M | -$0.93 | -$18.3M | -27.1% | -38.9% |
| FY2023 | $65.4M | -$33.0M | -$1.27 | -$19.9M | -41.5% | -38.8% |
| FY2022 | $45.5M | -$47.1M | -$1.91 | -$37.5M | -89.6% | -46.9% |
| FY2021 | $45.2M | -$36.1M | -$2.17 | -$25.0M | -52.5% | 419.7% |
| FY2020 | $41.1M | -$24.3M | -$1.45 | -$21.7M | -31.7% | 20.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NeuroPace Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NeuroPace Inc has historically struggled to out-earn its cost of capital, averaging just -20.9% ROIC.
NeuroPace Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NeuroPace Inc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-21.92 per share.